Brief: TiumBio Presents Phase 1b Interim Results for TU2218 in Combination with Pembrolizumab
01/06/2024 13:32
June 1 (Reuters) - TiumBio Co Ltd 321550.KQ :
* TIUMBIO CO: TU2218 WAS WELL-TOLERATED AS A MONOTHERAPY AND
COMBINATION THERAPY WITH PEMBROLIZUMAB, WITH NO DOSE LIMITING
TOXICITIES (DLTS) TO DATE
* : DATA FROM FULL PHASE 1B TRIAL, WHICH INCLUDES 18
PATIENTS,
WILL BE AVAILABLE IN SECOND HALF OF 2024
Source text for Eikon: ID:nPn8Gtn9sa
Further company coverage: 321550.KQ
((reuters.briefs@thomsonreuters.com;))
Recent news on TiumBio Co
See all newsBrief: TiumBio And Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial Of 'Merigolix For Uterine Fibroids
Brief: TiumBio Presents Phase 1b Interim Results for TU2218 in Combination with Pembrolizumab
Brief: TiumBio Submits CTA For Phase 1b Clinical Trial Of TU7710
Brief: Tiumbio To Initiate Phase 2 Trial Of Tu2218 For Cancer
Brief: Tiumbio And Hansoh Pharma Announce Clinical Trial Approval Of 'HS-10518/TU2670' From NMPA In China